HS#WUXI RC2612B

WuXi Biologics Anticipates 16.7% Revenue Growth to 21.79 Billion Yuan in 2025; Gross Margin to Increase by 5 Percentage Points to 46%

WuXi Biologics Reports Preliminary Full Year Net Profit Exceeding Expectations

WuXi Biologics Anticipates Revenue and Gross Margin Growth in 2025

WuXi Biologics Signs Innovative Tri-Specific TCE Development Agreement with Vertex Pharmaceuticals

WuXi Biologics Signs License and Research Agreement for Tri-specific T-cell Engager with Vertex Pharmaceuticals

WuXi Biologics and Sunovian Announce Strategic Collaboration on SND006 Process Development and Manufacturing

Morgan Stanley Reduced Stake in Wuxi Biologics (Cayman)

CLSA Report: Wuxi Biologics Outperforms Peers

WuXi Biologics and WuXi ChemPartner to Acquire at Least 60% of Tonox

CICC Maintains Buy Rating on Wuxi Biologics (Cayman)

Multiple HK-listed Companies Announce Major Updates

Major Wuxi Biologics Shareholder Sells Existing Shares

Wu Xiaosheng, CEO of WuXi Biologics, Speaks at JPM Healthcare Conference

Citi Group Launches Voluntary Cash Offer to Acquire eXiao Technology Cayman

WuXi Biologics and Zai Lab Sign TCE Research Collaboration Agreement

Morgan Stanley Maintains Wuxi Biologics 'Neutral' Rating, Raises Target Price

Daiwa Raises Target Price for Wuxi Biologics to HKD 42

WuXi Biologics' Wuxi Factories Obtain GMP Certification and Provide Ophthalmic Biologic Production

WuXi Biologics Briefs on 2026 Business Growth Prospects at Annual Healthcare Conference

WuXi Biologics Launches Global CRDMO Platform

PROSP INV HOLD

ELEGANCEOPTICAL

RIDGE OUTDOOR

LIFE CONCEPTS

HING LEE (HK)

TIANYE WATER

SHANGHAI QINGPU

K W NELSON GP

BJ DIGITAL

LAI SI ENT

02269

512290

WuXi BIO expects a 46% increase in net profit last year, exceeding RMB 4.9 billion, with a revenue growth of 16%. CHINA LIT issued a profit warning, expecting a full-year loss to widen to RMB 750 million to 850 million, mainly due to goodwill impairment. Leading Intelligent's new stock debut performed well, with a maximum gain of RMB 74. SMIC's profit grew by 60.66% last quarter, with sales revenue of USD 2.48 billion. ZEEKR released the world's first general-purpose warehouse robot Gino 1. Baoshan International's January revenue decreased by 32.5% year-on-year

Tasty Money

WUXI BIO

Guotai CSI Bio-medicine ETF

Huaan Hang Seng Biotech ETF

Tianhong CNI BIOMEDICINE ETF

CHINA LIT

China Southern Hang Seng Biotech ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

[Daily Announcement] WUXI BIO (2269) expects a 46% increase in net profit last year, CHINA LIT (772) issues a profit warning, expecting an expanded annual loss

513700

588860

588250

WuXi Biologics (Cayman) Inc shares rose 4.1% to HK$41.68, reaching a four-month high. The company anticipates a 46.3% increase in 2025 profit to 4.91 billion yuan ($710.21 million) and a 16.7% rise in revenue to 21.79 billion yuan. The gross profit margin is expected to improve by 5 percentage points to 46%. This growth is attributed to expanded services, increased research revenue, and efficiency improvements. Year-to-date, the stock is up 29.9%, outperforming the Hang Seng Biotech Index, which is up 13.3%.

Reuters

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ICBCCS SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

CAM HSBIOTECH

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

WuXi Biologics climbs to 4-month high on robust earnings estimates

The Hang Seng Index opened 63 points higher, reporting at 27,246 points. WUXI BIO expects a 46.3% increase in net profit last year, with its stock price opening 3.54% higher; SMIC reported a net profit of USD 173 million in the fourth quarter of last year, with its stock price opening 2.3% lower. In the U.S. stock market, the Dow Jones rose slightly, while the S&P 500 and Nasdaq fell. Tech stocks showed mixed performance, with Tencent down over 1% and Alibaba slightly up. Southbound funds net bought HKD 84.8 million in Hong Kong stocks

- U.S. stocks showed mixed results, with the Dow Jones reaching a record high of 50,512 points, closing up 52 points or 0.1%.  
- The S&P 500 fell 23 points or 0.33%, while the Nasdaq decreased by 135 points or 0.59%.  
- Major tech stocks like Tesla increased by 1.89%, whereas others like Alphabet and Amazon experienced declines.

Stheadline

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

SMIC

The Hang Seng Index opened 63 points higher, WUXI BIO rose 3.5% on positive earnings, and SMIC fell 2% | Hong Kong stock market opens

WXXWY

WuXi Biologics (Cayman) Inc. expects its revenue for 2025 to rise by 16.7% to RMB21.79 billion, with a gross profit margin projected to increase by 5 percentage points to 46.0%. Adjusted gross profit is anticipated to reach approximately RMB10.64 billion, reflecting a year-on-year growth of 25.5%. The company credits this growth to the ramp-up of its European manufacturing facility, cost savings, efficiency improvements, and investment gains.

Direxion S&P Biotech Bear 3X

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

WuXi Biologics

Ark Genomic Revolution ETF

SPDR S&P Biotech

VG Health

iShares US Pharma

iShares Global Healthcare

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

Wuxi Biologics Expects 2025 Revenue to Rise 16.7% to RMB21.79 Billion

WuXi Biologics (Cayman) :FY REVENUE RMB 21,790 MILLIONFY PROFIT EXPECTED TO INCREASE TO RMB5,733 MILLIONFY ADJUSTED NON-IFRS NET PROFIT EXPECTED TO INCREASE TO RMB6,586 MILLION

ChinaAMC SSE Health Care ETF Initiating Fund

Ping An CSI Medicine and Medical Device Innovation ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Wuxi Biologics FY Revenue RMB21,790 Million

WUXI BIO's preliminary annual revenue data is RMB 21.79 billion, with market estimates at RMB 21.54 billion. WUXI BIO's preliminary annual net profit data is RMB 4.91 billion, with market estimates at RMB 4.42 billion. WUXI BIO's preliminary annual gross margin data is 46%

Wallstreetcn

Wuxi Biologics (Cayman) Inc. will hold a Board of Directors meeting on March 24, 2026, to consider and approve the annual results for the year ended December 31, 2025, along with its publication. For further details, refer to the official announcement from the company.

WuXi Biologics Board to Approve Annual Results

JP Morgan listed the companies affected by the appreciation of the RMB on the earnings of Chinese stocks, indicating that a 5% appreciation of the RMB against the USD will negatively impact the net profits of several companies. The affected companies include SHENZHOU INTL, Super Ocean International, SMIC, USISH, COWELL, Longi Green Energy, SINOCERA MATERIAL, Zhejiang Dingli, Sany, XCMG, WUXI BIO, WUXI XDC, Jereh Holdings, and Sinopec Oilfield Service, with an expected impact range of 7% to 15%

AASTOCKS

A BOS RMB MM-R

SHENZHOU INTL

Sany

A BOS RMB MM

WUXI XDC

SINOCERA MATERIAL

A VP RMB MM

USISH

COWELL

XCMG

JP Morgan lists the Chinese stocks that are most negatively impacted by the appreciation of the RMB (Table)

01093

01801

08189

01177

08037

02509

The Hang Seng Biotechnology Index rose over 4% intraday, CSPC PHARMA rose over 7%, INNOVENT BIO rose nearly 7%, WUXI BIO and SINO BIOPHARM rose over 5%

CSPC PHARMA

INNOVENT BIO

TEDA BIOMEDICAL

SINO BIOPHARM

CH BIOTECH SER

QYUNS-B

WuXi Biologics (Cayman) Inc. has been awarded the EcoVadis Platinum Medal for the third consecutive year, ranking in the top 1% of over 150,000 companies assessed globally. The company’s sustainability efforts include approved greenhouse gas emissions reduction targets and a Green CRDMO White Paper on green technologies. WuXi Biologics has also received recognition for its ESG performance, including an MSCI AAA Rating and inclusion in the FTSE4Good Index Series.

WuXi Biologics Receives EcoVadis Platinum Medal for Third Consecutive Year

589720

Innovent Biologics Inc. reported a 45% year-over-year growth in product revenue for 2025, totaling approximately RMB11.9 billion. In Q4 2025, product revenue reached around RMB3.3 billion, also showing significant growth. The company recognized inventory price adjustments due to the addition of six new drugs to the 2026 National Reimbursement Drug List. This financial information is based on internal records and has not been audited. The original content was published via the Hong Kong Stock Exchange.

Guotai SSE STAR Brand Name Drug ETF

Innovent Biologics Reports 45% Year-Over-Year Growth in 2025 Product Revenue

VRTX

WuXi Biologics and Vertex Pharma signed a licensing and research service agreement regarding the innovative trispecific T cell engagers (TCE). Vertex Pharma will obtain the global exclusive development and commercialization rights for the TCE, while WuXi Biologics will receive an upfront payment as well as subsequent milestone payments and sales royalties, and will provide integrated contract research and development services

Vertex Pharma

WuXi Biologics and Vertex Pharma have reached a licensing and research service agreement for innovative tri-specific TCE

WuXi Biologics has signed a license and research service agreement with Vertex Pharmaceuticals for a trispecific T-cell Engager aimed at treating B-cell mediated autoimmune diseases. Vertex gains exclusive global rights for development and commercialization, while WuXi will receive upfront and milestone payments, along with royalties. This collaboration highlights WuXi's leadership in discovery service solutions and commitment to advancing transformative therapies.

StockTitan

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager | VRTX Stock News

The Hang Seng Index opened higher, refreshing its nearly four-year high; Tencent's performance exceeded expectations, receiving collective bullish calls from major banks; Chip stocks strengthened on the logic of domestic substitution, with SMIC leading the gains; Ping An's stake increase in China Taiping H-shares ignited the insurance sector; Cryptocurrency concept stocks surged as Bitcoin hit a new high; In the pharmaceutical sector, Jingtai Holdings reported its first profit, rising over 11%, while East Buy saw a sudden 12% increase.

Tencent

TENCENT

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Ping An Insurance

PING AN

PING AN-R

Ping An Ins HK SDR2to1

Ping An

SMIC HK SDR 5to1

CPIC

CHINA TAIPING

SUNSHINE INS

Life and Health Insurance

REMEGEN

RemeGen

BEONE MEDICINES

BeOne Medicines

Beigene

FI2 CSOP HSI

HUA HONG SEMI

Hua Hong

INNOCARE

InnoCare Pharma

GRANDSHORES

AKESO

HORIZONROBOT-W

ZA ONLINE

SINOHOPE TECH

GUOTAI JUNAN I

XTALPI

Life Sciences Tools and Services

XL2CSOPHSTECH

Semiconductors

FL2 CSOP HSI

LINEKONG

OKG TECH

Interactive Media and Services

CSOP HS TECH

XI2CSOPHSTECH

EAST BUY

Hot Trades in Hong Kong Stocks (8.14) | Hang Seng Index Hits Four-Year High at Opening, Morgan Stanley Says Foreign Capital Accelerated Inflows into Chinese Stock Market in July

Hong Kong stocks' innovative medicine sector surges 66%, three-pronged approach ignites the golden track

WUXI APPTEC

WuXi AppTec

3SBIO

DUALITYBIO-B

HENGRUI PHARMA

Hengrui Pharma

JOINN

Hong Kong stocks' innovative drugs surge 66%! Three major catalysts ignite the 'golden track', can we still get on board in the second half of the year?

On July 11, the three major stock indices in Hong Kong rose together. In terms of sectors, technology stocks rose collectively, and securities and brokerage stocks mostly increased.

LAOPU GOLD

POP MART

MIXUE GROUP

GUMING

AIA Group

LIANLIAN

OSL GROUP

PICC P&C

MAO GEPING

BLOKS

The Hang Seng Index is approaching its highest level in nearly 3 years, with Chinese brokerage, insurance, and stablecoin concept stocks remaining hot!

HS#WUXI RC2612B(57890.HK)